SolaranRx, Inc. is a pre-clinical company developing a new class of therapies and companion imaging agents for the treatment of metastatic melanoma. SolaranRx precisely targets deadly melanoma tumors with a radiolabeled peptide, offering unique therapeutic potential with minimal side effects. Our novel peptide
technology shows highly specic binding to melanoma enabling physicians to identify patients for treatment, deliver targeted radiation to melanoma tumors and visualize patient response. SolaranRx is focused on developing its lead product (SRX-1177), which has led to Orphan Drug designation by the FDA based on
compelling pre-clinical evidence. SolaranRx is strongly differentiated in the projected $5.6 billion global melanoma drug market by offering a distinctive mechanism of action that avoids the shortcomings of current therapies.